This is an aggregated industry headline. Read the full story at BioPharma Dive →
A PureTech startup banks $180M for a new IPF drug
Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.
By BioPharma Dive
· Jul 2, 2026
· via BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
The ad uses hand-crafted puppets to portray sight-based frustrations for those with presbyopia, a common condi…
The WeekFierceBiotech ↗
Roche's investigational KRAS G12C inhibitor has beaten Amgen's Lumakras and Bristol Myers Squibb's Krazati in …
The WeekBriefing
CMS is again proposing reduced Medicare payments for 340B drugs, reopening a long fight over hospital margins …